ClinicalTrials.gg
RecruitingNCT05134246CRICSUpdated Mar 3, 2025

Carotid Revascularization for Radiation Induced Carotid Artery Stenosis

An observational study in Radiation-induced Carotid Artery Stenosis, sponsored by Xuanwu Hospital, Beijing. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-03.

Sponsored by Xuanwu Hospital, Beijing · Observational

How we know

From the registry’s dates

  • Started Jan 2020; still recruiting 6 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing — 5 open to participants now, 6 under way, none of them phase 3. Carotid Stenosis · Xuanwu Hospital, Beijing.

Started
2020
the only one that year
Observational
6 of 11
3 open now
Registered
6th of 11
by date

Among the 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing, this one is the only one that started in 2020, is one of 6 observational ones, and was the 6th registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

5 of the 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Carotid Stenosis by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

Cervical radiotherapy (RT) has greatly reduced the mortality of patients with malignant head and neck tumors, which, however, causes a higher risk of carotid artery stenosis, namely, radiation-induced carotid artery stenosis (RICS) and results in a significant increased risk of ischemic stroke. The systematic review and meta-analysis conducted by our team showed carotid endarterectomy (CEA) can yield better results for these patients than carotid artery stenting (CAS), which was contrary to most previous clinical guidelines. A large-scale prospective study is needed to verify the results. We will conduct a prospective registry of RICS patients treated with CEA to evaluate both short-term safety and long-term efficacy outcomes in a Chinese population.

03

Conditions studied

  • Radiation-induced Carotid Artery Stenosis

Browse trials for

Keywords

  • Radiation-induced carotid artery stenosis
  • Carotid endarterectomy
  • Outcomes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with RICS and fulfilled the above eligible criteria in tertiary medical centers in China, will be enrolled consecutively.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with carotid stenosis who had a history of radiotherapy for head and neck cancer. (The median interval between the completion of radiation therapy and development of carotid artery stenosis detected on imaging (or vascular intervention) was no less than 1 years to avoid non-related situations. The target area of the radiotherapy included at least the ipsilateral neck, including part of the carotid system. The internal carotid stenosis was confirmed by angiography, Duplex, 3D angio-CTA or angio-MRI, and stenosis was defined as > 50% based on North American Symptomatic Carotid Endarterectomy Trial criteria), with or without symptom. Patients with a (TIA) or stroke within 6 months were defined as symptomatic. TIA was defined as a transient episode of neurological dysfunction (focal weakness/ language disturbance/transient monocular blindness/ requiring assistance to walk) caused by focal brain or retinal ischemia that lasts for at least 10 min but resolves within 24 h.)

Exclusion criteria

Exclusion Criteria:

  • The patients treated for restenosis.
  • Intracranial arteriovenous malformation or aneurysm
  • Severe stenosis or occlusion of the ipsilateral intracranial artery
  • Unstable angina, myocardial infarction (MI), or congestive heart failure in the last 6 months
  • Uncorrectable coagulation abnormalities
  • Uncontrolled diabetes mellitus defined as glucose > 300 mg/dL (16.67 mmol/L)
  • Pregnant or in the perinatal period
  • Severe concomitant disease with poor prognosis ( \< 2 years)
  • Intolerance or allergies to any of the study medications, such as aspirin or clopidogrel
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Carotid endarterectomy (CEA)

    Patients who are treated with CEA.

    Procedure: Carotid endarterectomy (CEA)

  • Carotid artery stenting (CAS)

    Patients who are treated with CAS.

    Procedure: Carotid artery stenting (CAS)

Interventions

  • ProcedureCarotid endarterectomy (CEA)

    Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.

  • ProcedureCarotid artery stenting (CAS)

    Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, local anaesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is mandatory for all patients who undergo CAS.

06

What researchers measure

Primary outcomes

  1. Stroke or death within 1 month

    A composite of any stroke or death occurring within 1-month post-procedure.

    Time frame: Within 1-month post-procedure

Secondary outcomes

  1. Stroke beyond 1 month within 1 year

    Stroke beyond 1 month within 1 year

    Time frame: Beyond 1-month and within 1 year post-procedure

  2. Death beyond 1 month within 1 year

    Death beyond 1 month within 1 year

    Time frame: Beyond 1-month and within 1 year post-procedure

  3. Stroke or death within 1 year

    Stroke or death within 1 year

    Time frame: Within 1 year post-procedure

  4. Cranial nerve injury

    Number of participants who suffered from cranial nerve injury

    Time frame: Within 1-month post-procedure

  5. Carotid artery restenosis

    Number of participants who suffered from carotid artery restenosis (\> 50%) detected by ultrasonography, CTA, or DSA

    Time frame: Within 1-year post-procedure

  6. Functional outcome

    Functional outcome indicated by NIHSS (National Institutes of Health Stroke Scale: 0-42; higher scores indicate worse outcome) or mRS (modified Rankin Scale: 0-6; higher scores indicate worse outcome)

    Time frame: Within 1-year post-procedure

  7. Other major complications

    Other major complications, such as myocardial infarction, incision hematoma, pulmonary infection, etc.

    Time frame: Within 1-month post-procedure

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Please contact the PI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Dec 2026, 83 months after the start.

Of 79 non-industry observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 104. This study's planned 83 months is above that.

Counting every sponsor, half of 87 studies reached it within 50 months; a quarter within 30 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2021
First posted
Nov 24, 2021
StartActual
Jan 5, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05134246
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
Jan 5, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 3, 2025

Study contacts

Tao Wang, MD
Contact
wangtao_dr@sina.com
18810302298
Liqun Jiao, MD
Contact
liqunjiao@sina.cn
13911224991
Liqun Jiao, MD
study chair · Xuanwu Hospital, Beijing
Tao Wang, MD
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion